Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07630792

Telerehabilitation Versus Face-to-Face LSVT BIG in Individuals With Parkinson Disease

This prospective, randomized controlled trial will enroll 40 individuals with idiopathic PD (Hoehn & Yahr stages 1-3, MoCA ≥21). Participants will be randomly assigned in a 1:1 ratio to either a telerehabilitation LSVT BIG group or a face-to-face LSVT BIG group, with randomization stratified by Hoehn & Yahr stage using a computer-based block randomization system. Both groups will receive the standard LSVT BIG® protocol consisting of 16 sessions over four weeks (4 days/week, 1 hour/session). Treatment content will include maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks. The telerehabilitation group will receive all sessions via synchronous video conferencing under physiotherapist supervision, while the face-to-face group will receive sessions in a clinical setting. Both groups will be assigned home exercise programs in accordance with the LSVT BIG® protocol, and treatment adherence will be monitored throughout the study.

Outcomes will be assessed at baseline, after 4 weeks of treatment, and at 6-month follow-up. Primary outcomes include postural stability and fall risk assessed with the Biodex Balance System (anterior-posterior stability index, mediolateral stability index, general stability index, fall risk index, limits of stability) and motor and non-motor symptom severity assessed with the MDS-UPDRS (Parts I, II, and III). Secondary outcomes include dynamic balance (Mini-BESTest), functional mobility (Timed Up and Go Test, 10-Meter Walk Test), quality of life (PDQ-39), depression (Beck Depression Inventory), sleep quality (Parkinson's Disease Sleep Scale), fatigue (Parkinson Fatigue Scale), cognitive function (MoCA), and treatment satisfaction (Global Rating of Change Scale).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

PARKINSON DISEASE (Disorder) Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinson Disease (PD), Postural Balance Parkinsonian Disorders Synucleinopathies

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of idiopathic Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • Montreal Cognitive Assessment (MoCA) score ≥ 21
  • Ability to use a smartphone, tablet, or computer
  • Access to internet connection and basic digital literacy
  • Participation in activities outside the home at least 3 days per week

Exclusion criteria

  • Diagnosis of a neurological condition other than idiopathic Parkinson's disease
  • Change in antiparkinsonian medication regimen during the study period
  • History of deep brain stimulation
  • Visual or hearing impairment that would prevent participation in treatment or assessments
  • Severe cardiovascular, orthopedic, pulmonary, or systemic comorbidity contraindicating exercise
  • Diagnosis of severe depression, psychotic disorder, or uncontrolled psychiatric illness
  • Participation in another structured physiotherapy or rehabilitation program for
  • Parkinson's disease within the last three months

Treatment and study plan

Face-to-Face LSVT BIG

Other

The standard LSVT BIG® protocol will be delivered in a clinical setting by a certified physiotherapist. The protocol consists of 16 sessions over four weeks (4 days/week, 1 hour/session). Treatment content includes maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks. Home exercises will be assigned on treatment days (once) and non-treatment days (twice daily) in accordance with the standard LSVT BIG® protocol.

Telerehabilitation LSVT BIG

Other

The standard LSVT BIG® protocol will be delivered via synchronous video conferencing under physiotherapist supervision. The protocol consists of 16 sessions over four weeks (4 days/week, 1 hour/session). Treatment content includes maximal daily exercises, functional component tasks, "big" gait training, and individually tailored hierarchy tasks. Home exercises will be assigned on treatment days (once) and non-treatment days (twice daily) in accordance with the standard LSVT BIG® protocol.

Primary outcomes

  1. Biodex Balance System

    Time frame: Baseline, Week 4, Month 6

  2. Movement Disorder Society-Unified Parkinson's Disease Rating Scale

    Time frame: Baseline, Week 4, Month 6

    Motor and non-motor symptom severity will be assessed using Parts I, II, and III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Part I evaluates non-motor symptoms, Part II evaluates motor aspects of daily living, and Part III evaluates clinician-rated motor signs. Each item is scored from 0 (normal) to 4 (severe), with higher total scores indicating greater symptom severity.

Secondary outcomes

  1. Mini-Balance Evaluation Systems Test

    Time frame: Baseline, Week 4, Month 6

    Dynamic balance will be assessed using the 14-item Mini-Balance Evaluation Systems Test, evaluating postural responses, anticipatory postural adjustments, dynamic gait, and sensory orientation. Each item is scored from 0 to 2, with a maximum total score of 28. Higher scores indicate better balance performance.

  2. Timed Up and Go Test

    Time frame: Baseline, Week 4, Month 6

    Functional mobility and dynamic balance will be assessed by measuring the time (in seconds) required to rise from a chair, walk 3 meters, turn, and return to sitting. Longer completion times indicate poorer functional mobility.

  3. Parkinson's Disease Questionnaire-39

    Time frame: Baseline, Week 4, Month 6

    Health-related quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire-39, covering 8 domains. Each item is scored from 0 to 4, with domain scores ranging from 0 to 100. Higher scores indicate worse quality of life.

  4. Beck Depression Inventory

    Time frame: Baseline, Week 4, Month 6

    Depressive symptoms will be assessed using the 21-item Beck Depression Inventory. Each item is scored from 0 to 3, with total scores ranging from 0 to 63. Higher scores indicate greater severity of depressive symptoms.

  5. Parkinson's Disease Sleep Scale

    Time frame: Baseline, Week 4, Month 6

    Sleep quality and sleep-related disturbances will be assessed using the 15-item Parkinson's Disease Sleep Scale. Each item is scored on a visual analog scale from 0 to 10. Lower total scores indicate poorer sleep quality.

  6. Parkinson Fatigue Scale

    Time frame: Baseline, Week 4, Month 6

    Fatigue severity and its impact on daily functioning will be assessed using the 16-item Parkinson Fatigue Scale. Each item is scored from 1 to 5, with higher total scores indicating greater fatigue.

  7. Montreal Cognitive Assessment

    Time frame: Baseline, Week 4, Month 6

    Cognitive function will be assessed using the Montreal Cognitive Assessment, evaluating attention, executive functions, memory, language, visuospatial skills, abstract thinking, and orientation. Total scores range from 0 to 30, with higher scores indicating better cognitive performance.

  8. Global Rating of Change Scale

    Time frame: Week 4, Month 6

    Patient-perceived change in overall condition will be assessed using the Global Rating of Change Scale. Scores range from -2 (much worse) to +2 (much better), with higher scores indicating greater perceived improvement.

Sponsors and collaborators

Lead sponsor

Bezmialem Vakif University

Other

Collaborators

  • Istanbul University - Cerrahpasa

Registry information

Official study title

The Effects of Telerehabilitation and Face-to-Face LSVT BIG Method on Motor and Non-Motor Symptoms in Individuals With Parkinson Disease

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jun 5, 2026
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.